Meeting
2014 ASCO Annual Meeting
Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
Authors
Michael S. Gordon
Pinnacle Oncology Hematology, Scottsdale, AZ
Michael S. Gordon , Jose Lutzky , Donald P. Lawrence , Keith W. Orford , Andy Blake-Haskins , Alessandra Di Pietro , Paul B. Robbins , Mohammed M. Dar , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02027961
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9108)
DOI
10.1200/jco.2014.32.15_suppl.tps9108
Abstract #
TPS9108
Poster Bd #
309A
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
First Author: Paul B. Chapman
Poster
2015 ASCO Annual Meeting
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
First Author: Jennifer Ann Wargo
Poster
2014 ASCO Annual Meeting
Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.
First Author: Christine Mateus
Poster
2017 ASCO Annual Meeting
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
First Author: Alain Patrick Algazi